Expert Interview
Evaluating Celldex Therapeutics' Barzolvolimab (CDX-0159) for the Treatment of Chronic Spontaneous Urticaria (CSU)
Ticker(s): CLDXInstitution: Charité – Universitätsmedizin Berlin
- Assistant Professor, Head of the allergy inpatient care unit and the mastocytosis outpatient clinic at the Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin.
- Treats approximately 350 patients with Indolent Systemic Mastocytosis.
- Research focuses on the biology of mast cells and the pathophysiology of mast cell driven diseases; has participated in over 30 randomized clinical controlled trials.
Could you please explain the mechanism of action of Barzolvolimab (CDX-0159) and how it differentiates from other treatments available for CSU, particularly in its targeting of the KIT receptor?
Added By: slingshot_insightsBased on the Phase 2 study results, how does Barzolvolimab's efficacy compare to other CSU treatments, especially in patients who are refractory to antihistamines and omalizumab?
Added By: slingshot_insightsConsidering Barzolvolimab's performance in the trial, how does it address the unmet medical needs in CSU therapy?
Added By: slingshot_insightsFrom the data presented, how would you characterize the safety profile of Barzolvolimab? Were there any significant adverse events or side effects that clinicians should be aware of?
How significant are the findings regarding the UAS7 changes and clinical responses in the trial, and what implications might they have for the broader CSU patient population?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
